Puma closes patient enrolment in Phase III breast cancer trial of neratinib

Puma Biotechnology has completed patient enrolment in the Phase III NALA trial of its lead drug candidate PB272 (neratinib) for the treatment of HER2-positive metastatic breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news